Home » Posts tagged with » Stefan Oelrich
Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

German pharma giant Bayer has agreed to acquire US clinical-stage gene therapy company Asklepios BioPharmaceutical in a deal worth up to $4 billion. The portfolio of Asklepios BioPharmaceutical features investigational pre-clinical and clinical stage candidates, which are being developed for the treatment of neuromuscular, cardiovascular, central nervous system, and metabolic diseases. Asklepios BioPharmaceutical was established […]

October 26, 2020No CommentRead More

Bayer to acquire KaNDy Therapeutics to add menopause drug candidate

August 11, 2020 No Comment
Bayer to acquire KaNDy Therapeutics to add menopause drug candidate

Bayer has agreed to acquire KaNDy Therapeutics, a UK clinical-stage biotech company, in a deal worth up to $900 million, in a move to grow its drug development pipeline in women’s healthcare. Through the acquisition, the German healthcare company gains access to NT-814, a non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist in developmen for the treatment […]

Continue reading …

Bayer to fully acquire US cell therapy company BlueRock Therapeutics

August 8, 2019 No Comment
Bayer to fully acquire US cell therapy company BlueRock Therapeutics

Bayer acquisition of BlueRock Therapeutics : Bayer will take full ownership in US cell therapy company BlueRock Therapeutics for an enterprise value of up to $1 billion, as per the latest pharma acquisition news. Headquartered in Cambridge, BlueRock Therapeutics develops engineered cell therapies in the fields of neurology, cardiology, and immunology using its proprietary induced […]

Continue reading …